Nome exists to ensure every patient has a treatment, no matter how rare their disease. THE PROBLEM: 300 million people worldwide live with rare diseases (nearly 6% of humanity, more than 6x the population living with cancer). Yet 95% have zero treatment options. The science exists (DNA and RNA therapies work, and the FDA is more open than ever to personalized medicine), but the system is too slow, too expensive, and too fragmented. OUR SOLUTION: Nome's Operating System for Personalized Therapeutics™ makes it faster, simpler, and less expensive to bring personalized medicines to patients. We combine AI, proven therapeutic platforms (like ASOs and gene editing), and a vetted network of labs, clinicians, and regulatory experts to orchestrate the entire drug development process. We close the gap between "you have a diagnosis" and "here's what to do next," turning genetic diagnoses into treatment action plans in weeks, not years. HOW IT WORKS: 1. Free eligibility assessment determines if a personalized therapy is viable 2. Comprehensive therapeutic plan with clear next steps, time, cost, and risk/benefit analysis 3. We coordinate labs, manufacturers, regulators, and clinical partners OUR APPROACH: We're not disrupting existing players. We're building the missing infrastructure that connects all the fragmented pieces of personalized medicine. The orchestration layer that makes personalized medicine routine instead of rare. WHO WE SERVE: Patients and families | Clinicians and genetic counselors | Health systems | Pharmaceutical companies Start your free assessment: www.nome.bio
| Employees | 11 (11 on RocketReach) |
| Founded | 2025 |
| Industry | Biotechnology Research |
Looking for a particular Nome employee's phone or email?
Steven Ringel is the Founder and CEO of Nome.
11 people are employed at Nome.